Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics

被引:0
|
作者
Jörg Mahlich
Kerstin Olbrich
Adrian Wilk
Antonie Wimmer
Claus Wolff-Menzler
机构
[1] Health Economics and Outcomes Research,Düsseldorf Institute of Competition Economics (DICE)
[2] Janssen,Team Gesundheit
[3] Pharmaceutical Companies of Johnson & Johnson,Department of Psychiatry and Psychotherapy
[4] University of Düsseldorf,undefined
[5] Gesellschaft für Gesundheitsmanagement mbH,undefined
[6] Medical Affairs,undefined
[7] Janssen,undefined
[8] Pharmaceutical Companies of Johnson & Johnson,undefined
[9] University Medical Center Göttingen,undefined
[10] Georg-August-University,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:99 / 113
页数:14
相关论文
共 50 条
  • [21] Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
    Rosenheck, Robert A.
    Krystal, John H.
    Lew, Robert
    Barnett, Paul G.
    Fiore, Louis
    Valley, Danielle
    Thwin, Soe Soe
    Vertrees, Julia E.
    Liang, Matthew H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (09): : 842 - 851
  • [22] ORAL SUPPLEMENTATION AND CONCOMITANT MEDICATION IN THE TREATMENT OF SCHIZOPHRENIA WITH LONG-ACTING ATYPICAL ANTIPSYCHOTICS
    Ascher-Svanum, H.
    Peng, X.
    Montgomery, W.
    Faries, D. E.
    Lawson, A. H.
    Witte, M.
    Novick, D.
    Jemiai, N.
    Perrin, E.
    VALUE IN HEALTH, 2009, 12 (03) : A185 - A185
  • [23] The modern perspective for long-acting injectables antipsychotics in the patient-centered care of schizophrenia
    Pietrini, Francesco
    Albert, Umberto
    Ballerini, Andrea
    Calo, Paola
    Maina, Giuseppe
    Pinna, Federica
    Vaggi, Marco
    Boggian, Ileana
    Fontana, Maria
    Moro, Cesare
    Carpiniello, Bernardo
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 1045 - 1060
  • [24] ORAL SUPPLEMENTATION AND CONCOMITANT MEDICATION IN THE TREATMENT OF SCHIZOPHRENIA WITH LONG-ACTING ATYPICAL ANTIPSYCHOTICS
    Ascher-Svanum, Haya
    Peng, X.
    Montgomery, W.
    Faries, D.
    Lawson, A.
    Witte, M.
    Novick, D.
    Jemiai, N.
    Perrin, E.
    McDonnell, D. P.
    SCHIZOPHRENIA BULLETIN, 2009, 35 : 333 - 334
  • [25] MEDICATION ADHERENCE AND DISCONTINUATION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH ARIPIPRAZOLE ONCE-MONTHLY LONG-ACTING INJECTABLE VERSUS THOSE TREATED WITH ORAL ANTIPSYCHOTICS
    Greene, Mallik
    Yan, Tingjian
    Chang, Eunice
    Hartry, Ann
    Pulasky, Beth
    SCHIZOPHRENIA BULLETIN, 2018, 44 : S248 - S249
  • [26] The risk for readmission in schizophrenia patients treated with long-acting injectable (typical or atypical) versus oral antipsychotics
    Onn, R.
    Krivoy, A.
    Weizman, A.
    Hochman, E.
    Valevski, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S494 - S494
  • [27] Clinical and functional outcomes of patients with schizophrenia treated with risperidone long-acting injection versus oral antipsychotics
    Olivares, J. M.
    Morales, A. Rodriguez
    Diels, J.
    Povey, M.
    Lam, A.
    Zhao, Z.
    EUROPEAN PSYCHIATRY, 2008, 23 : S126 - S127
  • [28] Personal and social recovery of patients with schizophrenia in the treatment of long-acting antipsychotics
    Serazetdinova, V.
    Petrova, N.
    EUROPEAN PSYCHIATRY, 2020, 63 : S555 - S555
  • [29] Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain
    Arango, Celso
    Baeza, Inmaculada
    Bernardo, Miquel
    Canas, Fernando
    de Dios, Consuelo
    Diaz-Marsa, Marina
    Paz Garcia-Portilla, Maria
    Gutierrez-Rojas, Luis
    Manuel Olivares, Jose
    Rico-Villademoros, Fernando
    Rodriguez-Jimenez, Roberto
    Maria Sanchez-Morla, Eva
    Segarra, Rafael
    Crespo-Facorro, Benedicto
    REVISTA DE PSIQUIATRIA Y SALUD MENTAL, 2019, 12 (02): : 92 - 105
  • [30] Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges
    Haddad, Peter M.
    Correll, Christoph U.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (04) : 473 - 493